<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011309</url>
  </required_header>
  <id_info>
    <org_study_id>IDRI-LCVTC-202</org_study_id>
    <nct_id>NCT01011309</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDRI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDRI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety, and immunogenicity of an
      investigational vaccine being developed for the treatment of leishmaniasis, including
      cutaneous leishmaniasis (CL). The vaccine, identified as LEISH-F2 + MPL-SE, consists of a
      Leishmania protein (LEISH-F2) together with an adjuvant MPL-SE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2, randomized, open-label, controlled study to evaluate the efficacy, safety, and
      immunogenicity of the vaccine administered three times (10 μg LEISH-F2 + 25 μg MPL-SE on Days
      0, 28 and 56) in the treatment of adults and adolescents with CL compared to treatment with
      standard chemotherapy (20 mg/kg/day sodium stibogluconate for 20 days). The proportion cured
      in each group will be determined using clinical criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Date of Clinical Cure</measure>
    <time_frame>Day 84</time_frame>
    <description>Efficacy of immunotherapy with the LEISH-F2 + MPL-SE vaccine was compared to the efficacy of chemotherapy with sodium stibogluconate in the treatment of CL. Efficacy is measured by the date of clinical cure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events of Grade 1 Severity or Higher Occurring in ≥ 3 Patients During Active Treatment Phase of the Study.</measure>
    <time_frame>Day 0 through Day 84</time_frame>
    <description>Safety of immunotherapy with the vaccine was compared to the safety of chemotherapy with sodium stibogluconate. All adverse events are listed regardless of relatedness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG Antibodies and T-cell Cytokine Responses (IFN-g and IL-10)</measure>
    <time_frame>Days 0, 56 or 84, and 168</time_frame>
    <description>Immunogenicity of the vaccine was evaluated by measuring IgG antibody and T-cell responses to the LEISH-F2 protein and soluble Leishmania antigen (SLA). IgG antibodies were measured by ELISA and T-cell cytokine responses (IFN-g and IL-10) were measured by Luminex. Data is presented as median Post:Pre ratios comparing Days 56/84 or 168 to baseline at Day 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>LEISH-F2 + MPL-SE vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium stibogluconate (SSG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/kg/day IV for 20 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LEISH-F2 + MPL-SE</intervention_name>
    <description>10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56</description>
    <arm_group_label>LEISH-F2 + MPL-SE vaccine</arm_group_label>
    <other_name>There are no other names for the vaccine.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium stibogluconate</intervention_name>
    <description>20 mg/kg/day IV daily for 20 days</description>
    <arm_group_label>Sodium stibogluconate (SSG)</arm_group_label>
    <other_name>Marfan SSG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 12 years and &lt; 70 years of age. In the first stage of the study,
             only patients aged ≥ 18 years and &lt; 70 years will be enrolled. In the second stage,
             enrollment will also include adolescent patients aged ≥ 12 - &lt; 18 years.

          -  Must have a clinical diagnosis of cutaneous leishmaniasis confirmed by positive
             identification of Leishmania parasite and identification of L. peruviana by PCR.

          -  Lesions must be clear of any superinfection prior to enrollment.

          -  Female patients of childbearing age must have a negative serum pregnancy test at
             screening, a negative urine pregnancy test within 24 hours before the first
             vaccination or initiation of chemotherapy, must not be breast-feeding, and are
             required to use adequate contraception through Day 84 of the study. These precautions
             are necessary due to unknown effects that LEISH-F2 + MPL SE, sodium stibogluconate
             might have in a fetus or newborn infant.

          -  The following laboratory blood tests must have values within the normal ranges at
             screening: sodium, potassium, urea, total bilirubin, ALT, AST, glucose, creatinine,
             alkaline phosphatase, total WBC count and platelet count. Hemoglobin may exceed the
             ULN since patients reside in the Andes at very high altitude (up to 20 g/dL)

          -  The following serology tests must be negative at screening: HIV-1/2, hepatitis B
             surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All patients (or their
             parents) will receive HIV-related counseling prior to testing. Patients with positive
             HIV test results will be referred for counseling and treatment as appropriate.

          -  Potential study patients (or their guardians) must give written informed consent, be
             willing to be housed in Lima for a minimum of 20 days and up to 63 days, able to
             attend all required follow-up visits, have a permanent address, and be reachable by
             study site personnel.

        Exclusion Criteria:

          -  Infection with species other than L.peruviana as confirmed by PCR.

          -  Presence of eleven or more active cutaneous leishmaniasis lesions.

          -  The diameter of the ulcerated area of any single lesion is &gt;60 mm.

          -  Presence of lesions with superinfection at time of enrollment.

          -  History of mucocutaneous leishmaniasis or diagnosis of mucocutaneous leishmaniasis at
             screening.

          -  History of previous exposure to Leishmania vaccines.

          -  Known use of injected or oral corticosteroids within 6 weeks prior to the first
             vaccination or initiation of chemotherapy.

          -  Participation in another experimental protocol or receipt of any investigational
             products within 30 days prior to the first vaccination or initiation of chemotherapy.

          -  History of autoimmune disease or other causes of immunosuppressive states.

          -  History or evidence of any acute or chronic illness that, in the opinion of the study
             clinician, may interfere with the evaluation of the safety or the immunogenicity of
             the vaccine. (Patients presenting with concomitant illness will be referred for
             standard clinical care).

          -  History of use of any medication that, in the opinion of the study clinician, may
             interfere with the evaluation of the safety or the immunogenicity of the vaccine.

          -  History of significant psychiatric illness.

          -  Drug addiction including alcohol abuse.

          -  Patients with a history of previous anaphylaxis, severe allergic reaction to vaccines
             or unknown allergens, or allergic reaction to eggs.

          -  Patients who are unlikely to cooperate with the requirements of the study protocol.

          -  ECG with evidence of ventricular arrythmias ≥ 4 extra systoles per minute.

          -  Known allergy or contraindication to chemotherapy (e.g., known reaction to pentavalent
             antimonials, cardiopathy, myocarditis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Piazza, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>IDRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Medicina Tropical&quot;Alexander von Humboldt&quot;</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>September 16, 2013</results_first_submitted>
  <results_first_submitted_qc>September 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2013</results_first_posted>
  <last_update_submitted>November 15, 2013</last_update_submitted>
  <last_update_submitted_qc>November 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leishmaniasis</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with CL were actively recruited from Andean mountain regions endemic for transmission of Leishmania peruviana. Patients were treated in a medical clinic at the Instituto de Medicina Tropical ‘Alexander von Humboldt’, Universidad Peruana Cayetano Heredia, Lima, Peru.</recruitment_details>
      <pre_assignment_details>All eligible patients were randomized to treatment groups. One patient was mistakenly randomized (ineligible) and was not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Immunotherapy v1.4/1.5</title>
          <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 28, and 56.</description>
        </group>
        <group group_id="P2">
          <title>Immunotherapy v1.6</title>
          <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 14, and 28.</description>
        </group>
        <group group_id="P3">
          <title>Chemotherapy</title>
          <description>Sodium stibogluconate (SSG) given 20 mg/kg/day IV for 20 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immunotherapy v1.4/1.5</title>
          <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B2">
          <title>Immunotherapy v1.6</title>
          <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 14, and 28.</description>
        </group>
        <group group_id="B3">
          <title>Chemotherapy</title>
          <description>Sodium stibogluconate (SSG) given 20 mg/kg/day IV for 20 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="14.2"/>
                    <measurement group_id="B2" value="32.7" spread="6.8"/>
                    <measurement group_id="B3" value="40.2" spread="16.0"/>
                    <measurement group_id="B4" value="38.0" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Date of Clinical Cure</title>
        <description>Efficacy of immunotherapy with the LEISH-F2 + MPL-SE vaccine was compared to the efficacy of chemotherapy with sodium stibogluconate in the treatment of CL. Efficacy is measured by the date of clinical cure.</description>
        <time_frame>Day 84</time_frame>
        <population>Per-protocol population: All patients who received all three study injections if in the immunotherapy groups or at least 15 injections of SSG if in the chemotherapy group, and completed the Day 56 visit (Immunotherapy v1.6), the Day 84 visit (Immunotherapy v1.4/1.5), or the Day 56 or Day 84 visit (Chemotherapy group).</population>
        <group_list>
          <group group_id="O1">
            <title>Immunotherapy v1.4/1.5</title>
            <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Immunotherapy v1.6</title>
            <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 14, and 28.</description>
          </group>
          <group group_id="O3">
            <title>Chemotherapy</title>
            <description>Sodium stibogluconate (SSG) given 20 mg/kg/day IV for 20 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Date of Clinical Cure</title>
          <description>Efficacy of immunotherapy with the LEISH-F2 + MPL-SE vaccine was compared to the efficacy of chemotherapy with sodium stibogluconate in the treatment of CL. Efficacy is measured by the date of clinical cure.</description>
          <population>Per-protocol population: All patients who received all three study injections if in the immunotherapy groups or at least 15 injections of SSG if in the chemotherapy group, and completed the Day 56 visit (Immunotherapy v1.6), the Day 84 visit (Immunotherapy v1.4/1.5), or the Day 56 or Day 84 visit (Chemotherapy group).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical cure by Day 84 without rescue treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical cure by Day 84 with rescue treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events of Grade 1 Severity or Higher Occurring in ≥ 3 Patients During Active Treatment Phase of the Study.</title>
        <description>Safety of immunotherapy with the vaccine was compared to the safety of chemotherapy with sodium stibogluconate. All adverse events are listed regardless of relatedness.</description>
        <time_frame>Day 0 through Day 84</time_frame>
        <population>Safety population: All patients who received at least one study injection.</population>
        <group_list>
          <group group_id="O1">
            <title>Immunotherapy v1.4/1.5</title>
            <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Immunotherapy v1.6</title>
            <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 14, and 28.</description>
          </group>
          <group group_id="O3">
            <title>Chemotherapy</title>
            <description>Sodium stibogluconate (SSG) given 20 mg/kg/day IV for 20 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events of Grade 1 Severity or Higher Occurring in ≥ 3 Patients During Active Treatment Phase of the Study.</title>
          <description>Safety of immunotherapy with the vaccine was compared to the safety of chemotherapy with sodium stibogluconate. All adverse events are listed regardless of relatedness.</description>
          <population>Safety population: All patients who received at least one study injection.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superinfection bacterial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgG Antibodies and T-cell Cytokine Responses (IFN-g and IL-10)</title>
        <description>Immunogenicity of the vaccine was evaluated by measuring IgG antibody and T-cell responses to the LEISH-F2 protein and soluble Leishmania antigen (SLA). IgG antibodies were measured by ELISA and T-cell cytokine responses (IFN-g and IL-10) were measured by Luminex. Data is presented as median Post:Pre ratios comparing Days 56/84 or 168 to baseline at Day 0.</description>
        <time_frame>Days 0, 56 or 84, and 168</time_frame>
        <population>Per-protocol population: patients who received all three study injections (immunotherapy groups) or at least 15 SSG injections (chemotherapy group) and completed the Day 84 or Day 56 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Immunotherapy v1.4/1.5</title>
            <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Immunotherapy v1.6</title>
            <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 14, and 28.</description>
          </group>
          <group group_id="O3">
            <title>Chemotherapy</title>
            <description>Sodium stibogluconate (SSG) given 20 mg/kg/day IV for 20 days.</description>
          </group>
        </group_list>
        <measure>
          <title>IgG Antibodies and T-cell Cytokine Responses (IFN-g and IL-10)</title>
          <description>Immunogenicity of the vaccine was evaluated by measuring IgG antibody and T-cell responses to the LEISH-F2 protein and soluble Leishmania antigen (SLA). IgG antibodies were measured by ELISA and T-cell cytokine responses (IFN-g and IL-10) were measured by Luminex. Data is presented as median Post:Pre ratios comparing Days 56/84 or 168 to baseline at Day 0.</description>
          <population>Per-protocol population: patients who received all three study injections (immunotherapy groups) or at least 15 SSG injections (chemotherapy group) and completed the Day 84 or Day 56 visit.</population>
          <units>Relative ELISA Units</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG antibody to LEISH-F2 - Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Immunogenicity not measured at Day 56 in Immunotherapy v1.4/1.5.</measurement>
                    <measurement group_id="O2" value="84.56" lower_limit="40.99" upper_limit="409.8"/>
                    <measurement group_id="O3" value="2.004" lower_limit="0.392" upper_limit="37.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG antibody to LEISH-F2 - Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.72" lower_limit="31.19" upper_limit="577.1"/>
                    <measurement group_id="O2" value="NA">Immunogenicity not measured at Day 84 in Immunotherapy v1.6.</measurement>
                    <measurement group_id="O3" value="0.662" lower_limit="0.176" upper_limit="104.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG antibody to LEISH-F2 - Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.93" lower_limit="6.74" upper_limit="159.6"/>
                    <measurement group_id="O2" value="10.26" lower_limit="9.11" upper_limit="80.75"/>
                    <measurement group_id="O3" value="0.74" lower_limit="0.24" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG antibody to SLA - Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Immunogenicity not measured at Day 56 in Immunotherapy v1.4/1.5.</measurement>
                    <measurement group_id="O2" value="1.36" lower_limit="0.46" upper_limit="3.14"/>
                    <measurement group_id="O3" value="0.59" lower_limit="0.17" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG antibody to SLA - Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.84" upper_limit="4.43"/>
                    <measurement group_id="O2" value="NA">Immunogenicity not measured at Day 84 in Immunotherapy v1.6.</measurement>
                    <measurement group_id="O3" value="0.54" lower_limit="0.11" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG antibody to SLA - Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.15" upper_limit="2.88"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.08" upper_limit="1.19"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.05" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g response to LEISH-F2 - Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Immunogenicity not measured at Day 56 in Immunotherapy v1.4/1.5.</measurement>
                    <measurement group_id="O2" value="4.97" lower_limit="0.354" upper_limit="38.36"/>
                    <measurement group_id="O3" value="1.09" lower_limit="0.003" upper_limit="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g response to LEISH-F2 - Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.042" upper_limit="19.13"/>
                    <measurement group_id="O2" value="NA">Immunogenicity not measured at Day 84 in Immunotherapy v1.6.</measurement>
                    <measurement group_id="O3" value="1.333" lower_limit="0.073" upper_limit="296.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g response to LEISH-F2 - Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.04" upper_limit="4.76"/>
                    <measurement group_id="O2" value="2.06" lower_limit="0.41" upper_limit="11.3"/>
                    <measurement group_id="O3" value="0.82" lower_limit="0.15" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g response to SLA - Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Immunogenicity not measured at Day 56 in Immunotherapy v1.4/1.5.</measurement>
                    <measurement group_id="O2" value="0.87" lower_limit="0.09" upper_limit="6.1"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.01" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g response to SLA - Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.02" upper_limit="39.7"/>
                    <measurement group_id="O2" value="NA">Immunogenicity not measured at Day 84 in Immunotherapy v1.6.</measurement>
                    <measurement group_id="O3" value="0.89" lower_limit="0.09" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g response to SLA - Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.01" upper_limit="76.5"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.05" upper_limit="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 response to LEISH-F2 - Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Immunogenicity not measured at Day 56 in Immunotherapy v1.4/1.5.</measurement>
                    <measurement group_id="O2" value="3.16" lower_limit="0.4" upper_limit="12.8"/>
                    <measurement group_id="O3" value="1.22" lower_limit="0.06" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 response to LEISH-F2 - Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" lower_limit="0.57" upper_limit="47.2"/>
                    <measurement group_id="O2" value="NA">Immunogenicity not measured at Day 84 in Immunotherapy v1.6.</measurement>
                    <measurement group_id="O3" value="1.17" lower_limit="0.06" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 response to LEISH-F2 - Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="0.16" upper_limit="27.5"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.44" upper_limit="3.48"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.08" upper_limit="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 response to SLA - Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Immunogenicity not measured at Day 56 in Immunotherapy v1.4/1.5.</measurement>
                    <measurement group_id="O2" value="1.02" lower_limit="0.64" upper_limit="2.68"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.03" upper_limit="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 response to SLA - Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.15" upper_limit="25.2"/>
                    <measurement group_id="O2" value="NA">Immunogenicity not measured at Day 84 in Immunotherapy v1.6.</measurement>
                    <measurement group_id="O3" value="0.92" lower_limit="0.04" upper_limit="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 response to SLA - Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" lower_limit="0.062" upper_limit="308.9"/>
                    <measurement group_id="O2" value="0.565" lower_limit="0.294" upper_limit="1.068"/>
                    <measurement group_id="O3" value="0.763" lower_limit="0.177" upper_limit="3.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 through Day 336.</time_frame>
      <desc>All SAEs are listed regardless of relatedness. Other adverse events listed are considered possibly, probably, or definitely related to study vaccination or chemotherapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Immunotherapy v1.4/1.5</title>
          <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 28, and 56.</description>
        </group>
        <group group_id="E2">
          <title>Immunotherapy v1.6</title>
          <description>10 mcg LEISH-F2 antigen + 25 mcg MPL-SE adjuvant given as three subcutaneous injections on Days 0, 14, and 28.</description>
        </group>
        <group group_id="E3">
          <title>Chemotherapy</title>
          <description>Sodium stibogluconate (SSG) given 20 mg/kg/day IV for 20 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to Antimonial Toxicity</sub_title>
                <description>Unrelated to vaccination. Headache, nausea, vomiting, abdominal pain and oral discomfort. Lab tests: potassium 2.1mmol/L (Grade 4); AST 66U/L (Grade 1); ALT 35U/L (Grade 1); WBC 3900/mm3 (Grade 1); hgb 10.9g/dL (Grade 1); platelets 65K/mm3 (Grade 2).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hospitalization due to Grade 3 Cellulitis</sub_title>
                <description>Unrelated to study vaccination. First and second degree burns caused by spilled hot water on left thigh and knee. The subject was treated immediately; pain was well controlled and subsided within 24 hours.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="21" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" events="21" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" events="25" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>WBC decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>IDRI encourages publication in peer-reviewed medical journals and will not unduly withhold permission to publish. However, all proposed publications, papers, abstracts or written materials related to the study or an outline of any oral presentation, shall be submitted to and coordinated by IDRI to assure that no proprietary information is presented and that authorship is fairly represented.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A total of 150 patients was planned, including age de-escalation to adolescents after the first 60 adults enrolled. Owing to slow recruitment and insufficient evidence of efficacy in the immunotherapy group, enrollment was closed early.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jill Ashman, MSc, Associate Director of Clinical Operations</name_or_title>
      <organization>IDRI</organization>
      <phone>206-858-6041</phone>
      <email>jill.ashman@idri.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

